Videos

The assistant professor of medicine in the Division of Blood and Marrow Transplantation and Cellular Therapy at Stanford University discussed the safety and efficacy results he presented at EHA’s 2023 congress.

The associate professor at Medical College of Wisconsin discussed new findings from the CARTITUDE-4 study.

The assistant professor in the Division of Hematologic Malignancies and Cellular Therapeutics at the University of Kansas Medical Center discussed real-world safety outcomes for brexu-cel in patients with r/r MCL.

The director of University of Washington Medicine’s Cancer Vaccine institute discussed results from a phase 1 study presented at ASCO’s 2023 conference.

The PhD candidate from University of North Carolina – Chapel Hill discussed preclinical research presented at ASGCT 2023.

The assistant professor in the Division of Hematologic Malignancies and Cellular Therapeutics at the University of Kansas Medical Center discussed the real-world data she is presenting at EHA’s 2023 congress.

The associate professor at Medical College of Wisconsin discussed the rationale for the CARTITUDE-4 study and its latest updates.

The associate professor at University College London also discussed unmet needs that remain in r/r B-ALL and another presentation of interest at ASCO’s 2023 conference.

The professor of medicine and pediatrics at Washington University in St. Louis discussed evaluating afami-cel in the SPEARHEAD-1 trial.

The director of the Lymphoma Clinical Research Program at University of Texas MD Anderson Cancer Center discussed the implications of overall survival data that he presented at ASCO’s 2023 conference.

The professor of medicine and pediatrics at Washington University in St. Louis discussed updated survival data from SPEARHEAD-1.

The associate professor in haemato-oncology at University College London discussed Autolus Therapeutics’ CAR-T, which utilizes a novel fast off-rate CD19 binding domain.

The chief scientific officer at Omega Therapeutics discussed positive preclinical data presented at ASCO 2023.

The scientist at Senti Biosciences discussed developing small molecule-regulated gene circuits.

The chief scientific officer of LocanaBio discussed preclinical data with an AAV-delivered, snRN, exon 51 skipping approach presented at ASGCT 2023.

The assistant professor of microbiology at Penn Medicine discussed research into characterizing type 1 interferon and EGR2 signaling and their effects on CAR T-cell activation.

The senior scientist at Tune Therapeutics discussed preclinical research presented at the ASGCT 2023 meeting.

The principal investigator at Seattle Children’s Research Institute discussed her lab’s preclinical research on nonviral delivery methods for gene editing tools in the context of treating hemophilia A.

The principal investigator at Seattle Children’s Research Institute discussed the preclinical research on delivery methods for genomic medicines that her lab presented at ASGCT’s 2023 meeting.

The pediatric gastroenterologist and professor in residence at University of California at San Francisco discussed updated data from the phase 1/2 CAMPSIITE trial presented at ASGCT 2023.

The CEO, founder, and president of Siren Biotechnology discussed the preclinical data she presented at ASGCT’s 2023 meeting on the use of AAV immuno-gene therapy for high-grade gliomas.

The chief scientific officer at Candel Therapeutics discussed late-breaking data presented at ASGCT 2023.

The senior investigator at the National Cancer Institute Center for Cancer Research discussed updated data from a phase 1/2 trial presented at ASGCT 2023.

The professor of internal medicine at UT Southwestern Medical Center shared his perspective on the current landscape of CAR-T cell therapy in the care of patients with myeloma.

The chief scientific officer of Sangamo Therapeutics discussed the company’s AAV capsid evolution research.

The neurologist at Massachusetts General Hospital discussed BBP-812, an investigational AAV vector-based gene therapy being evaluated for Canavan disease in a phase 1/2 trial.

The chief scientific officer of Sangamo Therapeutics discussed data from 2 of the company’s programs that were presented at ASGCT’s 2023 conference.

The senior scientist at Eterna Therapeutics discussed the company’s numerous presentations at ASGCT’s 2023 conference.

The vice president of research at Prime Medicine discussed a preclinical study on a novel autologous HSCT treatment that was presented at ASGCT’s 2023 annual meeting.

The professor at Ohio State University and University of California – San Francisco discussed updated data from a phase 1 study of GDNF gene therapy in patients with PD.